The mild MHT activates the systemic immune response and combines with PD‐L1 siRNA to inhibit cancer.[205] After AMF radiation, the tumor‐associated drugs are exposed to the generated tumor debris and collaborated with adjuvant to offer tumor vaccine‐like functions. This evidence concerns the gene CD274 and cancer.